From Wikipedia, the free encyclopedia
Pharmaceutical drug
Daunorubicin/cytarabine , sold under the brand name Vyxeos , is a
fixed-dose combination medication used for the treatment of
acute myeloid leukemia .
[4]
[6] It contains the liposomal bound
daunorubicin , an
anthracycline topoisomerase inhibitor , and
cytarabine , a nucleoside metabolic inhibitor.
[4]
Medical uses
Daunorubicin/cytarabine is
indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.
[4]
[7]
[8]
[9]
[10]
References
^
a
b
"Vyxeos APMDS" . Therapeutic Goods Administration (TGA) . 15 June 2022.
Archived from the original on 18 June 2022. Retrieved 18 June 2022 .
^
"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)" . nctr-crs.fda.gov .
FDA . Retrieved 22 October 2023 .
^
"Health product highlights 2021: Annexes of products approved in 2021" .
Health Canada . 3 August 2022. Retrieved 25 March 2024 .
^
a
b
c
d
"Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension" . DailyMed . 13 April 2021.
Archived from the original on 29 March 2021. Retrieved 18 June 2022 .
^
"Vyxeos liposomal EPAR" .
European Medicines Agency (EMA) . 23 August 2018. Retrieved 25 May 2024 .
^ Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P (June 2022).
"CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML" . Cancers . 14 (12): 2843.
doi :
10.3390/cancers14122843 .
PMC
9221356 .
PMID
35740508 .
^
"Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more" . Medscape .
Archived from the original on 15 August 2017. Retrieved 19 March 2019 .
^
"Vyxeos (cytarabine and daunorubicin) FDA Approval History" . Drugs.com .
Archived from the original on 11 April 2019. Retrieved 30 December 2018 .
^ Chen EC, Fathi AT, Brunner AM (2018).
"Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML" . OncoTargets and Therapy . 11 : 3425–3434.
doi :
10.2147/OTT.S141212 .
PMC
6003284 .
PMID
29928134 .
^ Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica . 111 (5): 455–466.
doi :
10.23736/S0026-4806.20.07017-2 .
PMID
32955826 .
S2CID
221842680 . {{
cite journal }}
: CS1 maint: overridden setting (
link )